Norbert Bischofberger, Kronos CEO
Three more biotechs look to jump onto Nasdaq amid IPO boom, including Norbert Bischofberger's Kronos
Three drug developers announced plans to go public on Friday, a sign that the IPO window for biopharma is wide open.
First up is …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
